Vertex Pharmaceuticals (VRTX)

Sector:Health Care
Super Investor Stats:
Ownership count:2
Ownership rank:481
% of all portfolios:0.032%
Hold Price * :$446.52
History Portfolio Manager Activity Share change % change to portfolio
Q1  2026
Tweedy Browne Add 3.16% 1,239 0.04
Torray Funds Reduce 0.52% 80 0.01
Q4  2025
Torray Funds Reduce 4.85% 789 0.06
Tweedy Browne Add 0.21% 83 0.00
Q3  2025
Tweedy Browne Add 4.86% 1,812 0.06
Torray Funds Reduce 3.70% 624 0.03
Q2  2025
Torray Funds Add 7.37% 1,158 0.07
Tweedy Browne Reduce 2.77% 1,063 0.04
Q1  2025
Tweedy Browne Reduce 5.70% 2,315 0.10
Torray Funds Reduce 1.79% 287 0.02
Q4  2024
John Armitage - Egerton Capital Sell 100.00% 124,045 0.58
Tweedy Browne Reduce 24.20% 12,969 0.35
Torray Funds Add 1.63% 257 0.01
Q3  2024
John Armitage - Egerton Capital Buy 124,045 0.58
Torray Funds Add 13.01% 1,813 0.12
Tweedy Browne Reduce 1.37% 746 0.02
Q2  2024
Tweedy Browne Reduce 18.52% 12,353 0.27
Torray Funds Add 0.28% 39 0.00
Q1  2024
Torray Funds Reduce 1.20% 169 0.01
Lee Ainslie - Maverick Capital Sell 100.00% 812 0.01
Q4  2023
Torray Funds Buy 14,068 0.93
Lee Ainslie - Maverick Capital Reduce 44.27% 645 0.01
Q3  2023
Lee Ainslie - Maverick Capital Buy 1,457 0.01
Q4  2021
Lee Ainslie - Maverick Capital Sell 100.00% 18,052 0.04
Q3  2021
Lee Ainslie - Maverick Capital Buy 18,052 0.04
Q2  2021
Lee Ainslie - Maverick Capital Sell 100.00% 6,254 0.01
Q1  2021
Lee Ainslie - Maverick Capital Buy 6,254 0.01
Q2  2020
Lee Ainslie - Maverick Capital Sell 100.00% 460 0.00
Q1  2020
Lee Ainslie - Maverick Capital Buy 460 0.00
Q2  2015
Lee Ainslie - Maverick Capital Sell 100.00% 524,867 1.00
Q1  2015
Lee Ainslie - Maverick Capital Buy 524,867 1.00
Q2  2009
Bill & Melinda Gates Foundation Trust Sell 100.00% 95,000 0.03
Q1  2009
Bill & Melinda Gates Foundation Trust Buy 95,000 0.03

* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.